Development and Validation of Analytical Methods for Radiochemical Purity of <sup>177</sup>Lu-PSMA-1

Development and Validation of Analytical Methods for Radiochemical Purity of <sup>177</sup>Lu-PSMA-1

Prostate Specific Membrane Antigen (PSMA) is a highly relevant target in nuclear medicine due to its overexpression in prostate cancer. The <sup>68</sup>Ga/<sup>177</sup>Lu-PSMA-1 combination is a theranostic agent for the detection and treatment of tumors overexpressing the...

Full description

Bibliographic Details
Main Authors:	Pauline Orhon, Marie-Dominique Desruet, Marie Piquemal, Nicolas De Leiris, Loïc Djaileb, Jean-Philippe Vuillez, Pierrick Bedouch, Julien Leenhardt
Format:	Article
Language:	English
Published:	MDPI AG 2022-04-01
Series:	Pharmaceuticals
Subjects:	radioligand therapy prostate cancer radiochemical purity <sup>177</sup>Lu-PSMA-1 validation of analytical methods high-performance liquid chromatography (HPLC)
Online Access:	https://www.mdpi.com/1424-8247/15/5/522

Similar Items

Improvement of End-of-Synthesis Radiochemical Purity of <sup>177</sup>Lu-DOTA-PSMA-Ligands with Alternative Synthesis Approaches: Conversion Upswing and Side-Products Minimization
by: Anton Larenkov, et al.
Published: (2024-11-01)

Quality Assurance Investigations and Impurity Characterization during Upscaling of [<sup>177</sup>Lu]Lu-PSMA<sup>I&T</sup>
by: Stefan Schmitl, et al.
Published: (2023-11-01)

[<sup>177</sup>Lu]Lu-PSMA-617 (Pluvicto<sup>TM</sup>): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer
by: Ute Hennrich, et al.
Published: (2022-10-01)

RadioLigand Therapy with [<sup>177</sup>Lu]Lu-PSMA-617 for Salivary Gland Cancers: Literature Review and First Compassionate Use in France
by: Marie Terroir, et al.
Published: (2023-05-01)

Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using <sup>177</sup>Lu-iPSMA and <sup>177</sup>Lu-DOTATOC: Experience after 905 Treatment Doses
by: Myrna Luna-Gutiérrez, et al.
Published: (2023-07-01)

<sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice
by: Kim N. Chi, et al.
Published: (2024-03-01)

Correlation of an Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after <sup>177</sup>Lu-PSMA-617 Radioligand Therapy
by: Friederike Völter, et al.
Published: (2021-03-01)

Hematological Toxicity in Mice after High Activity Injections of <sup>177</sup>Lu-PSMA-617
by: Amanda Kristiansson, et al.
Published: (2022-03-01)

Features and Practical Aspects of Radiochemical Purity Determination of Receptor-Specific Lu-177 Radiopharmaceuticals as Exemplified by [<sup>177</sup>Lu]Lu–PSMA-617
by: A. A. Larenkov, et al.
Published: (2022-12-01)

<sup>177</sup>Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
by: Yasemin Sanli, et al.
Published: (2021-04-01)

Optimized Therapeutic <sup>177</sup>Lu-Labeled PSMA-Targeted Ligands with Improved Pharmacokinetic Characteristics for Prostate Cancer
by: Yitian Wu, et al.
Published: (2022-12-01)

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [<sup>177</sup>Lu]Lu-OPS201 Compared to the Agonist [<sup>177</sup>Lu]Lu-DOTA-TATE
by: Rosalba Mansi, et al.
Published: (2021-12-01)

Production and Quality Control of [<sup>177</sup>Lu]Lu-PSMA-I&T: Development of an Investigational Medicinal Product Dossier for Clinical Trials
by: Valentina Di Iorio, et al.
Published: (2022-06-01)

Efficacy and Safety of [<sup>225</sup>Ac]Ac-PSMA-617 Augmented [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis
by: Florian Rosar, et al.
Published: (2021-05-01)

Toxicity Assessment of [<sup>177</sup>Lu]Lu−iFAP/iPSMA Nanoparticles Prepared under GMP-Compliant Radiopharmaceutical Processes
by: Tania Hernández-Jiménez, et al.
Published: (2022-11-01)

Recovery of <sup>177</sup>Lu from Irradiated HfO<sub>2</sub> Targets for Nuclear Medicine Purposes
by: Andrey G. Kazakov, et al.
Published: (2022-05-01)

Early treatment response assessment with [177Lu]PSMA whole-body-scintigraphy compared to interim PSMA-PET
by: David Ventura, et al.
Published: (2024-09-01)

<sup>177</sup>Lu-PSMA-617 Therapy in Mice, with or without the Antioxidant α<sub>1</sub>-Microglobulin (A1M), Including Kidney Damage Assessment Using <sup>99m</sup>Tc-MAG3 Imaging
by: Amanda Kristiansson, et al.
Published: (2021-02-01)

Organ and tumor dosimetry including method simplification for [177Lu]Lu-PSMA-I&T for treatment of metastatic castration resistant prostate cancer
by: Amir Karimzadeh, et al.
Published: (2024-07-01)

Pretherapeutic PSMA PET-Derived Semiquantitative Parameters as Predictors of PSA Response in Patients with mCRPC Receiving [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy
by: Dheeratama Siripongsatian, et al.
Published: (2024-10-01)

The therapeutic use of 177 Lu-PSMA-617 radioligand therapy in prostate cancer treatment: a review of literature and ongoing trials
by: Alexander Konopnicki, et al.
Published: (2024-12-01)

Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy
by: Florian Rosar, et al.
Published: (2021-05-01)

<sup>90</sup>Y/<sup>177</sup>Lu-DOTATOC: From Preclinical Studies to Application in Humans
by: Licia Uccelli, et al.
Published: (2021-09-01)

Lutathera<sup>®</sup> Orphans: State of the Art and Future Application of Radioligand Therapy with <sup>177</sup>Lu-DOTATATE
by: Luca Urso, et al.
Published: (2023-03-01)

First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [<sup>177</sup>Lu]Lu-DOTA.SA.FAPi and [<sup>177</sup>Lu]Lu-DOTAGA.(SA.FAPi)<sub>2</sub>
by: Sanjana Ballal, et al.
Published: (2021-11-01)

Assessment of salivary gland function after 177Lu-PSMA radioligand therapy: Current concepts in imaging and management
by: Sonia Mahajan, et al.
Published: (2022-07-01)

Quality control of [177Lu]Lu-PSMA preparations using HPLC: effect of sample composition and ligand on recovery
by: Else A. Aalbersberg, et al.
Published: (2022-09-01)

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [<sup>177</sup>Lu]Lu-Satoreotide Tetraxetan and the Agonist [<sup>177</sup>Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST<sub>2</sub>-Positive Tumours
by: Pascale Plas, et al.
Published: (2022-08-01)

Synthesis, Characterization, and Therapeutic Efficacy of <sup>177</sup>Lu-DMSA@SPIONs in Nanobrachytherapy of Solid Tumors
by: Dragana Stanković, et al.
Published: (2023-07-01)

USE OF <sup>177</sup>Lu-PSMA FOR RADIONUCLIDE THERAPY IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER
by: A. A. Medvedeva, et al.
Published: (2021-06-01)

Response Assessment and Prediction of Progression-Free Survival by <sup>68</sup>Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing <sup>177</sup>Lu-PSMA-617 Radioligand Therapy
by: Fadi Khreish, et al.
Published: (2021-07-01)

<sup>177</sup>Lu Anti-Angiogenic Radioimmunotherapy Targeting ATP Synthase in Gastric Cancer Model
by: Bok-Nam Park, et al.
Published: (2024-06-01)

177LU-PSMA AND 177LU-DOTATATE AS THERAPY ALTERNATIVES FOR METACHRONOUS TRANSDIFFERENTIATED PROSTATE AND NEUROENDOCRINE TUMORS - CASE REPORT
by: Beatriz Birelli do Nascimento, et al.
Published: (2024-04-01)

177Lu-PSMA radioligand therapy for isolated bilateral adrenal metastases from prostate cancer
by: Elisabetta Perrone, et al.
Published: (2024-07-01)

Radioactivity distribution in the blood and urine of patients receiving systemic therapy with a <sup>177</sup>Lu radiopharmaceutical and local (intra-articular) therapy with a <sup>188</sup>Re radiopharmaceutical
by: E. D. Stepchenkova, et al.
Published: (2022-12-01)

Radiochemical Feasibility of Mixing of <sup>99m</sup>Tc-MAA and <sup>90</sup>Y-Microspheres with Omnipaque Contrast
by: Chang-Tong Yang, et al.
Published: (2022-11-01)

Optimizing the Schedule of PARP Inhibitors in Combination with <sup>177</sup>Lu-DOTATATE: A Dosimetry Rationale
by: Andreas Hallqvist, et al.
Published: (2021-10-01)

Preparation and Preliminary Evaluation of Neurotensin Radiolabelled with <sup>68</sup>Ga and <sup>177</sup>Lu as Potential Theranostic Agent for Colon Cancer
by: Radu Anton Leonte, et al.
Published: (2021-04-01)

Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?
by: Felix Kind, et al.
Published: (2022-04-01)

In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2nd Cycle Is Better Predictor of Overall Survival of Prostate Cancer Patients Treated With 177Lu-PSMA
by: Vikas Prasad, et al.
Published: (2021-03-01)